CysLT 1
Montelukast (5 μM; 1 h) inhibits APAP-induced cell damage.
Montelukast (3 mg/kg; ora1 gavage) protects against APAP-induced hepatotoxicity in mice.
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor.
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice.